Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong ...

Verdence Capital Advisors LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.9% in the third quarter, according to the company in its most recent 13F ...

A $1000 investment made in November 2014 would be worth $6,540.57, or a gain of 554.06%, as of November 8, 2024, according to our calculations. This return excludes dividends but includes price ...

According to Benzinga Pro, Halozyme Therapeutics's peer group average for short interest as a percentage of float is 10.61%, which means the company has more short interest than most of its peers. Did ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Hold rating on Halozyme (HALO – Research Report), with a ...

Piper Sandler raised the firm’s price target on Halozyme (HALO) to $52 from $51 and keeps a Neutral rating on the shares. The firm notes ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zai Lab (NASDAQ:ZLAB) stock rose 5% in early trading Monday after the company announced that Vyvgart Hytrulo’s regulatory ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...

Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...